Role of chemotherapy in the very elderly patients with metastatic pancreatic cancer - A Veterans Affairs Cancer Registry analysis

被引:20
作者
Aldoss, Ibrahim T. [1 ,3 ]
Tashi, Tsewang [1 ,3 ,4 ]
Gonsalves, Wilson [1 ,3 ,4 ]
Kalaiah, Ranin K. [1 ,3 ,4 ]
Fang, Xiang [5 ]
Silberstein, Peter [1 ,3 ,4 ]
Ganti, Apar K. [2 ,3 ,4 ]
Subbiah, Shanmuga [1 ,3 ,4 ]
机构
[1] Creighton Univ, Med Ctr, Div Internal Med, Dept Hematol & Oncol, Omaha, NE 68131 USA
[2] Univ Nebraska Med Ctr, Dept Hematol & Oncol, Div Internal Med, Omaha, NE USA
[3] Dept Hematol & Oncol, Div Internal Med, Omaha, NE USA
[4] VA Nebraska Western Iowa Hlth Care Syst, Omaha, NE USA
[5] Creighton Univ, Dept Biostat, Omaha, NE 68131 USA
关键词
Chemotherapy; Elderly patients; Pancreatic cancer; PHASE-III TRIAL; CELL LUNG-CANCER; PLUS GEMCITABINE; 1ST-LINE TREATMENT; COMORBIDITY INDEX; RANDOMIZED-TRIAL; CLINICAL-TRIALS; SAFETY PROFILE; SURVIVAL; CISPLATIN;
D O I
10.1016/j.jgo.2011.02.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Metastatic pancreatic cancer is an incurable disease with dismal prognosis, ranging from 2 to 6 months. The role of chemotherapy for metastatic pancreatic cancer in very elderly patients (>= 80 years) has not been well studied. Methods: We reviewed all cases of metastatic pancreatic cancer in patients aged >= 80 years in the Veterans Affairs Central Cancer Registry (VACCR) from 1995 to 2007. Four hundred and forty patients were identified. Type of therapy received, tumor grade, tobacco history, sex and race were noted. Overall survival was calculated by log rank and Kaplan-Meier analysis. Baseline co-morbid conditions were scored using the Charlson co-morbidity index score (CCIS), a validated measure of patient co-morbidity. Results: Among the 440 eligible patients in the analysis, the majority received no therapy (83%), while only 12% received chemotherapy alone. Multivariate analysis demonstrated that chemotherapy was associated with significant superior median overall survival (4.9 months, 95% CI 3.57-5.77) compared to no therapy (1.7 months, 95% CI 0.9-1.3) (HR=0.41, p < 0.0001). One-year survival was higher in patients receiving chemotherapy compared to patients who received no therapy (13% vs. 3%). Current smoking was associated with decreased median overall survival compared to past or never smoking status (1.18 vs. 1.63 and 1.57 months respectively, p = 0.0087). Conclusion: Although the majority of elderly patients with metastatic pancreatic cancer do not receive any treatment, chemotherapy in this patient population was associated with improved median overall survival. Further randomized studies are warranted to confirm this observation. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:209 / 214
页数:6
相关论文
共 36 条
[1]   Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer [J].
Abou-Alfa, Ghassan K. ;
Letourneau, Richard ;
Harker, Graydon ;
Modiano, Manuel ;
Hurwitz, Herbert ;
Tchekmedyian, Nerses Simon ;
Feit, Kevie ;
Ackerman, Judie ;
De Jager, Robert L. ;
Eckhardt, S. Gail ;
O'Reilly, Eileen M. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (27) :4441-4447
[2]   Therapeutic options for elderly patients with advanced non-small cell lung cancer [J].
Avery, Eric J. ;
Kessinger, Anne ;
Ganti, Apar Kishor .
CANCER TREATMENT REVIEWS, 2009, 35 (04) :340-344
[3]   Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].
Burris, HA ;
Moore, MJ ;
Andersen, J ;
Green, MR ;
Rothenberg, ML ;
Madiano, MR ;
Cripps, MC ;
Portenoy, RK ;
Storniolo, AM ;
Tarassoff, P ;
Nelson, R ;
Dorr, FA ;
Stephens, CD ;
VanHoff, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413
[4]  
*CENS BUR US, 2005, 65 US 2005
[5]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[6]   Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma - A prospective, randomized phase III study of the Gruppo Oncologico dell'Italia Meridionale [J].
Colucci, G ;
Giuliani, F ;
Gebbia, V ;
Biglietto, M ;
Rabitti, P ;
Uomo, G ;
Cigolari, S ;
Testa, A ;
Maiello, E ;
Lopez, M .
CANCER, 2002, 94 (04) :902-910
[7]   Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study [J].
Colucci, Giuseppe ;
Labianca, Roberto ;
Di Costanzo, Francesco ;
Gebbia, Vittorio ;
Carteni, Giacomo ;
Massidda, Bruno ;
Dapretto, Elisa ;
Manzione, Luigi ;
Piazza, Elena ;
Sannicolo, Mirella ;
Ciaparrone, Marco ;
Cavanna, Luigi ;
Giuliani, Francesco ;
Maiello, Evaristo ;
Testa, Antonio ;
Pederzoli, Paolo ;
Falconi, Massimo ;
Gallo, Ciro ;
Di Maio, Massimo ;
Perrone, Francesco .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (10) :1645-1651
[8]   Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer [J].
Cunningham, David ;
Chau, Ian ;
Stocken, Deborah D. ;
Valle, Juan W. ;
Smith, David ;
Steward, William ;
Harper, Peter G. ;
Dunn, Janet ;
Tudur-Smith, Catrin ;
West, Julia ;
Falk, Stephen ;
Crellin, Adrian ;
Adab, Fawzi ;
Thompson, Joyce ;
Leonard, Pauline ;
Ostrowski, Joe ;
Eatock, Martin ;
Scheithauer, Werner ;
Herrmann, Richard ;
Neoptolemos, John P. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) :5513-5518
[9]   ADAPTING A CLINICAL COMORBIDITY INDEX FOR USE WITH ICD-9-CM ADMINISTRATIVE DATABASES [J].
DEYO, RA ;
CHERKIN, DC ;
CIOL, MA .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1992, 45 (06) :613-619
[10]  
DHOORE W, 1993, METHOD INFORM MED, V32, P382